Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209•Institute for Neurodegenerative Disorders

Summary

The underlying goal of this study is to assess \[18F\] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•The following criteria will be met for inclusion of AD subjects in this study:
•* The participant is 50 years or older.
•* Written informed consent is obtained.
•* Participants have a clinical diagnosis of probable Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.
•* Clinical Dementia Rating Scale score ≤ 2.
•* Modified Hachinski Ischemia Scale score of ≤ 4.
•* For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\]-PBR06 injection.
•The following criteria will be met for inclusion of PD subjects in this study:
•* The participant is 30 years or older.
•* Written informed consent is obtained.
+15 more criteria

Exclusion Criteria

•Alzheimer's subjects will be excluded from participation for the following reasons:
•* The subject has a history of significant cerebrovascular disease.
•* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
•* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
•* Pregnancy
•Parkinson's subjects will be excluded from participation for the following reasons:
•* The subject has a clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness
•* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
•* Pregnancy
•MS subjects will be excluded from participation for the following reasons:
+7 more criteria

Locations (1)

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

Key Dates

Start Date

November 1, 2009

Primary Completion Date

September 22, 2010

Completion Date

September 22, 2010

Last Updated

April 3, 2019

Enrollment

ESTIMATED participants

Conditions

Alzheimer DiseaseParkinson DiseaseMultiple Sclerosis

Interventions

[18F] PBR06

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease